SAMe 400


Supports a balanced mood

  • Boosts mood and emotional well-being
  • Relieves symptoms of osteoarthritis
  • Provides an effective dosage and a stable form of SAMe
  • Promotes methylation
Gluten Free
If you decide a subscription is not for you, it can be cancelled after 30 days

S-Adenosyl-L-Methionine (SAMe) is a natural compound and methyl group donor that supports the methylation cycle, a process which is essential for many aspects of health. Methylation is fundamental for ridding the body of certain toxins, and certain people, such as those with chronic liver disorders, cannot produce adequate levels of SAMe.

SAMe’s effectiveness to support a balanced mood is demonstrated by many clinical studies. SAMe is in fact so effective for boosting a low mood that it is legally registered as a prescription drug in several European countries for mood balance.  One study showed that SAMe was as effective as a common prescription medication for mood. It is thought that SAMe works by help boosting serotonin, dopamine and melatonin levels in the brain, low levels of which are commonly associated with mood imbalances such as anxiety and depression. SAMe has also been found to support joint health in osteoarthritis patients as effectively as a popular anti-inflammatory drug by reducing inflammation and protecting joint tissue from degradation.

AOR Advantage

AOR introduced the first SAMe supplement to Canada in 2000. SAMe can provide mood support, benefit those suffering from osteoarthritis, and is essential for those with liver disorders to maintain good health. AOR’s SAMe 400 provides an effective dosage and a stable form of this valuable compound in an enteric coated tablet for maximum effectiveness.




SAMe 400 is s-adenosyl-L-methionine (SAMe), a key biological factor that supports methylation, healthy mood function and the alleviation of symptoms and functional impairment in osteoarthritis. SAMe 400 utilizes a new, more stable, nonhygroscopic (unlikely to absorb moisture) source of SAMe.


AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard or dairy.

Adult Dosage

Take two or three tablets daily on an empty stomach, or as directed by a qualified health care practitioner. Use for a minimum of four weeks to see beneficial effects for osteoarthritic pain and a minimum of two weeks for mood support.


Do not take at night, since this product may cause anxiety, restlessness and insomnia. Consult a health care practitioner prior to use if you are pregnant or breastfeeding, suffer from depression or are taking medications which may influence serotonin levels (e.g. antidepressants).

Main Applications
  • Mood
  • Joint health
  • Liver health

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Serving Size: One Tablet
S-Adenosyl-L-Methioinine (SAMe)
400 mg

Non-medicinal Ingredients: stearic acid, magnesium hydroxide, microcrystalline cellulose, calcium oxide, shellac, arginine, magnesium stearate, silica, talc, sodium alginate and glycerol.


SAMe’s effectiveness as an anti-depressant is demonstrated in a plethora of clinical studies. The depth of many of these trials is also impressive, so much so that not only is SAMe legally registered as a prescription drug in Italy, Germany, Spain and Russia, but even the extremely influential U.S. Department of Health stated that SAMe’s effect on depression was ‘clinically significant’. More notably, it did so without categorizing SAMe as a drug.

SAMe’s anti-depressant activity is aptly demonstrated in many key human trials. One such trial in Italy in 1995 saw 195 patients being given 400 mg of SAMe (parenterally administered) for 15 days. Depressive symptoms remitted after both seven and 15 days of treatment, and no serious adverse events were reported, testimony to the speed of SAMe’s efficacy. Another study, this one in California a year earlier, directly compared SAMe with a tricyclic antidepressant called desipramine using 26 patients suffering from what was diagnosed as major depression. The two groups underwent treatment for four weeks, and at the conclusion of the study it was found that 62% of the SAMe patients had experienced significant improvement compared to the 50% of the desipramine patients who did so. ‘Significant improvement’ in this case was measured in accordance with the Hamilton Depression Rating Scale (HAM-D), a scientifically standardized method of measuring depression symptoms.

SAMe and Osteoarthritis

By a happy coincidence, many of the patients of the aforementioned SAMe trials for depression also noticed the simultaneous alleviation of their arthritic symptoms. In order to eliminate the possibility of attributing this to any residual placebo effect from the anti-depressant properties of SAMe, 10 studies were conducted specifically on osteoarthritis patients who were not diagnosed with depression. These studies involved a total of 22,000 participants in both Europe and the United States, and the general consensus from this massive collection of data is twofold. The first is that SAMe demonstrated clear efficacy in treating osteoarthritis compared to a placebo. The second is that SAMe possesses therapeutic effects similar to those of the standard non-steroidal anti-inflammatory agents (NSAIDs) used to treat osteoarthritis, but is better tolerated.

The mechanism of action for SAMe’s treatment of osteoarthritis indicates an ability to increase the synthesis and proliferation of proteoglycans. Furthermore, SAMe may effectively protect proteoglycans from decomposition by proteolytic and glycotic enzymes by promoting the growth of polyamines as a stabilizing factor for the proteoglycans. SAMe may also elicit its benefits on osteoarthritis through an anti-inflammatory capability as well. Evidence pointing to this includes the fact that SAMe can restore the condition of cultured synovial cells after they have been exposed to the damaging effects of pro-inflammatory cytokines.

SAMe and Liver Health

The fundamental metabolism of SAMe itself goes a considerable way in explaining its effectiveness in treating hepatic conditions, including carcinogenic ones. The importance of glutathione as an omnipresent antioxidant cannot be understated, and unsurprisingly hepatic glutathione is one of the chief antioxidants involved in hepatic detoxification. Hepatic glutathione is dependent on methionine and SAMe metabolism for its own biosynthesis, and up to 80% of hepatic methionine is converted into SAMe. Studies have shown that patients with a wide etiology of liver disorders share the common denominator of being unable to metabolize methionine or SAMe effectively. In fact, subsequent studies have revealed that sufferers of chronic liver disorders do not have sufficient concentrations of a liver-specific isoenzyme identified as MAT I/III, which seems to play an essential role in the conversion of methionine to SAMe. Conversely, MAT I/III is vulnerable to high concentrations of nitric oxide and low levels of glutathione. Supplemental SAMe has been shown to increase glutathione concentrations in hepatic tissue as well as in red blood cells in general.